• standardized
  • personalized
  • therapeutic
  • cancer vaccines

Immunicum AB (publ) develops cancer immunotherapies. The Company’s two main groups of therapeutic cancer vaccines, SUBCUVAX® and INTUVAX®, in addition to the method for expansion of tumor-specific T-cells (CD70), are based on the Nobel Prize awarded discovery of dendritic cells (DCs) and their central role in all immune responses. Immunicum’s products can be produced cost efficiently in large scale.

The therapeutic cancer vaccine INTUVAX® is injected intratumorally and has recently been evaluated in a finalized clinical Phase I/II-study in metastatic renal cell carcinoma showing promising survival data and clear indications of tumor specific immune activation. INTUVAX® utilizes each patient’s own unique tumor tissue as antigen source and is thus a completely standardized therapeutic cancer vaccine that is still able to offer a personalized treatment and store in frozen condition for long periods of time.

Om Immunicum


Immunicum is a biopharmaceutical company that was founded in 2002 as a spinoff from Sahlgrenska University Hospital, in Gothenburg, Sweden



Immunicum has three different platforms for the development of cancer immunotherapies



Immunicum has four ongoing projects, with a strong focus on the ongoing clinical trial in renal cell carcinoma

Investerare & Media


Press releases, financial reports, calendar, meetings/presentations, etc.

Latest news

Date changedRead more

FinancingRead more